NVAX ramped on the squeeze as crowd psychology and algorithmic logic took hold in the market crash last week. But this company has as much chance of participating in the actual vaccine as my aunt's family chicken soup recipe. We look for the fade.
NVAX - closing gaps! - fast down as mentioned... early. DROP HARD. as was mentioned it would do. early monring. (Now lets see where it goes from here after 10am.)
___________________________________
Disclaimer:
Always do your own due diligence, full research, and homework, and consult with your own licensed investment professional before any investments. Any...
Well for some reason the News is Killing the Market, I am down 60% Today, so decided to look at things with a different Light. Which ones Move differently depending on the Hype / News that is in our Ears.
Got this one for $10 and next day it was $16 that might be the top for this one but Maybe not? I did not draw on the Chart but you can see it took off like a...
This is an interesting idea based on outbreaks of SARS, MERS, and SARS-CoV-2 (2019).
Novavax successfully created vaccines for SARS, MERS, and are on track to create one for SARS-CoV-2 (2019) - ir.novavax.com
Vaccine in development for SARS-CoV-2 (2019): seekingalpha.com
Is this a good investment? If the vaccination is successful and/or coronavirus outbreak...
NVAX --- Jumped!!! from pre-hours trading. on OPEN. ---- CAN KEEP GOING UP ---- also - Take some prfts now to be safe -- IMO.
NOW sold the position for NOW taking the very nice profits off the table....
and then wait and see next move... The technical indicators shown that it could quickly reach that high and it did ---- now since it went so soon need to wait...
NVAX --- Great movement!! Very nice chart developing here --- but be very cautious.... I believe it will climb up to the 13.90 range... (after hours it already climbed and touched in the $13.00+ dollar range before it may reverse sharply and come straight down. Alwasy be very careful with any Pharmaceutical stocks --- as they can change direction and wipe...
NVAX -- Crazy climb!! In a try to reach a vaccine.... ZACKS pick The company’s expected earnings growth rate for the current year is 46% compared with the Zacks Medical - Biomedical and Genetics industry’s projected earnings growth of 8.1%. Novavax, Inc. NVAX is a late-stage biotechnology company that focuses on the discovery, development, and commercialization of...
NVAX is one, of all the COVID-2019 movers, that we think is most likely to end up being a great short down the line.
The long-term trajectory speaks of numerous failures to execute in clinical development, and the company is not part of the inside clique with funding to solve the virus vaccine puzzle. But it's up almost 100% since the news first broke last month.
NVAX
The "inevitability bell" may be starting to ring on this one. We called it short a few days ago -- and 7% higher. And now we may be seeing this start to play along. If short with us here, stops should be set in place in the $8.75 area to fence off the unbounded squeeze risk.
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and...
Gap play. NVAX is in stage 3 of a trial to treat influenza. This is a huge money maker. Net Income has been on a steady climb up. with a solid product this could take off. has broken the 200 day EMA for the first time in a long time. slight pull back at the moment.
NVAX
NVAX breaking out as a notable "Wuhan Coronavirus" play after company hit the wires with dev plan for vaccine candidate.
But the company has a history of under-delivering in key moments. This is a momo headline play, but after the fever breaks, so will the stock.
NVAX coronavirus panic. Currently, several biotech shares rose significantly yesterday. The driving force is a fundamental fear of the coronavirus. NVAX is one of the potential candidates who can isolate and solve the problem. The fair value of NVAX stock is currently around USD 11.5. Technically, the stock price is in the right place. But what about panic? Is...
A comany that is capable of designing a vaccine for coronavirus.
It is difficult to say whether the price spike is due to the capability or their recent drug clinical trials succeeding.
NVAX’s innovation outlook is neutral based on a current score of 55 out of 99, outperforming sector average. Jobs growth over the past year has decreased and insiders sentiment is neutral. Over the past 4 quarters NVAX beat earnings estimates 1 time. For more analysis and articles visit our website .
